Tough blow for Novartis: General Court confirms that mark representing transdermal patch is invalid
The General Court has upheld a decision of the EUIPO finding that Novartis’ figurative EU trademark, which represents the company’s Exolon transdermal patch, was invalid.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the WTR experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10